EUVIMEDEUVIMED entdecken
Crossref

Single‐dose psilocybin superior to placebo for MDD in community setting

The Brown University Psychopharmacology Update · 2026-12 · 37 (12) · 3-3

DOI: 10.1002/pu.31520 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 14.11.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Major depressive disorder (MDD) affects about 300 million people worldwide. About one‐third of these have treatment‐resistant depression (TRD), commonly defined as a failure to respond to two antidepressants. Although these conditions represent a major public health problem, access to specialized treatments is limited.

Zitieren

APA

(2026). Single‐dose psilocybin superior to placebo for MDD in community setting. The Brown University Psychopharmacology Update, 37(12), 3-3. https://doi.org/10.1002/pu.31520

Vancouver

Single‐dose psilocybin superior to placebo for MDD in community setting. The Brown University Psychopharmacology Update. 2026;37(12):3-3. doi:10.1002/pu.31520

BibTeX
@article{euvimed2026,
  title = {Single‐dose psilocybin superior to placebo for MDD in community setting},
  journal = {The Brown University Psychopharmacology Update},
  year = {2026},
  volume = {37},
  number = {12},
  pages = {3--3},
  doi = {10.1002/pu.31520}
}
Kostenlos starten →